AIDS (London, England) · 1992
AIDS-associated mucocutaneous Kaposi's sarcoma treated with bleomycin.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Caumes E, Guermonprez G, Katlama C, Gentilini M
Аннотация
OBJECTIVES: To evaluate efficacy and tolerance of bleomycin in AIDS-associated mucocutaneous Kaposi's sarcoma. A previous study showed that bleomycin was effective and well tolerated in this setting.
DESIGN: A non-comparative, open, prospective study.
METHODS: Seventy patients were treated with 5 mg per day intramuscular bleomycin on 3 consecutive days every 2 weeks.
RESULTS: Two patients achieved a complete response and 50 a partial response (overall response rate, 74%). Median time to treatment response was 4 weeks (range, 2-12 weeks) and median time to relapse 10 weeks (range, 2-36 weeks). Dose-limiting toxicity consisted of cutaneous adverse reactions.
CONCLUSION: Bleomycin is active against AIDS-associated mucocutaneous Kaposi's sarcoma; relapse occurs after discontinuation of therapy.
DESIGN: A non-comparative, open, prospective study.
METHODS: Seventy patients were treated with 5 mg per day intramuscular bleomycin on 3 consecutive days every 2 weeks.
RESULTS: Two patients achieved a complete response and 50 a partial response (overall response rate, 74%). Median time to treatment response was 4 weeks (range, 2-12 weeks) and median time to relapse 10 weeks (range, 2-36 weeks). Dose-limiting toxicity consisted of cutaneous adverse reactions.
CONCLUSION: Bleomycin is active against AIDS-associated mucocutaneous Kaposi's sarcoma; relapse occurs after discontinuation of therapy.